Translational Research Program (TRP)
The Translational Research Program (TRP) by the Leukemia & Lymphoma Society funds advanced blood cancer research ready for clinical translation and near-term patient impact.
Funder: Leukemia & Lymphoma Society
Due Dates: October 16, 2026 (Letter of Intent) | January 22, 2027 (Full application)
Funding Amounts: Up to $250,000/year, maximum $750,000 over 3 years (includes up to 10% indirect costs).
Summary: Supports translational research projects moving promising blood cancer discoveries toward clinical application, emphasizing near-term clinical impact.
Key Information: Only projects with robust translational readiness and proof-of-concept data are competitive; early-stage/discovery work is not eligible.
Description
The Translational Research Program (TRP) supports projects that accelerate the movement of promising scientific discoveries into clinical applications for blood cancers. The program is designed for research with a clear translational pathway and potential for near-term clinical impact, including the development of novel therapies, personalized medicine approaches, improvements in stem cell transplantation, and innovative immunotherapies. TRP places special emphasis on aggressive or hard-to-treat hematologic malignancies and projects with strong proof-of-concept data. Early-stage or discovery-focused research is not suitable for this program and should be directed to the Discovery Grant Program.
